Eli Lilly reports its experimental drug more than doubled Ozempic's weight loss in a phase 3 study of people with diabetes.
Recap by typeshit. Post by Facebook on Facebook.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
Mounjaro brought in $10.7 billion and Zepbound $5.4 billion. Lilly says about seven in 10 Medicare Bridge patients use its drugs, while Foundayo hit $184 million.
Loading…